If memory problems are making it hard to track doses, the first step is a formal medication review — and Medicare Part D plans must offer eligible enrollees one free every year. It is called a Comprehensive Medication Review: an interactive consultation with a pharmacist or qualified provider that covers every prescription, over-the-counter drug, herbal product and supplement, followed by a written summary mailed to the enrollee.
That review matters more than a better pillbox, because the problem is usually the size of the regimen, not the container. More than 4 in 10 US adults aged 65 and older took five or more prescription drugs in a recent 30-day period, according to a JAMA analysis of national survey data, up from about 21.9% in 1999–2000. Fewer drugs, taken on simpler schedules, is the fix that lasts.
Table of Contents
- Why memory loss breaks dose tracking faster than people expect
- What the free Medicare review actually gets you
- Does a memory diagnosis qualify someone?
- The drugs most worth questioning
- Questions to bring, and what to settle before you leave
- Where the guidance runs out
- Frequently Asked Questions
Why memory loss breaks dose tracking faster than people expect
Cognitive change does not cause occasional slips; it undercuts the specific mental work that taking medication requires. A systematic review of 15 studies of community-dwelling people with cognitive impairment or dementia, published in PLOS ONE, found adherence ranging from only 10.7% to 38% — consistently worse than in people without cognitive impairment. The same review identified which abilities are tied to adherence: new learning, memory and executive function.
That explains a pattern families often misread. Someone can recall a decades-old routine perfectly and still be unable to absorb a new twice-daily dose, or to hold the plan in mind while deciding whether this morning's dose already happened. It also means a warning sign is not forgetfulness in general but forgetfulness aimed at the regimen: a pill organizer with doses left in past compartments, refills arriving too early or too late, or the person asking repeatedly whether they have taken something.
What the free Medicare review actually gets you
The Comprehensive Medication Review is a person-to-person or telehealth consultation, not a form. Because it covers supplements and over-the-counter products alongside prescriptions, it catches interactions that no single prescriber sees — the sleep aid bought at a pharmacy counter, the herbal supplement nobody wrote down. The written summary that follows is standardized, and that is what makes it useful to a caregiver.
Medicare.gov's page on medication therapy management describes a "Recommended To-Do List" and a "Medication List" with space to write notes and follow-up questions. A family member can work straight from those two pages: one lists actions, the other becomes the single accurate record to bring to every appointment. Bring to the appointment, ideally in a bag:.
- Every prescription bottle, including ones from specialists and mail order
- Over-the-counter drugs, vitamins, herbals and supplements
- Eye drops, inhalers, patches and creams, which people routinely forget to mention
- A note on which doses are actually being missed, and at what time of day
Does a memory diagnosis qualify someone?
Alzheimer's disease now helps qualify. Effective January 1, 2025, CMS requires Part D sponsors to include 10 core chronic diseases — Alzheimer's among them — in their medication therapy management targeting criteria, per the agency's CY2025 program submission memo. There is a real limit here.
In the April 2025 CY2026 final rule, CMS declined to add dementias other than Alzheimer's to that core list, deferring the question to later rulemaking. A diagnosis of vascular dementia or Lewy body dementia does not by itself trigger eligibility. Targeting criteria also weigh drug count and drug cost, so many people with other dementias still qualify on those grounds — polypharmacy is common in exactly this group. If the plan says no, ask the pharmacy directly: many pharmacists will do a paid or complimentary medication review outside the Medicare program, and the annual wellness visit is another place to raise the full list.
The drugs most worth questioning
Two classes deserve direct attention when memory is already affected. The 2023 update of the AGS Beers Criteria — the standard list of potentially inappropriate medications in older adults — advises avoiding anticholinergic drugs in older adults with dementia or cognitive impairment, and avoiding benzodiazepines in people who have or are at high risk of delirium. Anticholinergics are easy to miss because the label rarely says so. They include many older antihistamines, some bladder medications, certain antidepressants and antispasmodics, several of them sold without a prescription.
A reviewer who sees the whole list can count the total anticholinergic load, which no individual prescriber can do alone. Stopping a drug is its own procedure, not a cancellation. A September 2025 deprescribing roadmap specific to dementia in Drugs & Aging, from Johns Hopkins and Kaiser Permanente Colorado authors, sets out four steps: identify deprescribing targets, build a tapering plan, complete supporting actions, and provide close follow-up. It deliberately centers care partners, because dementia's course varies and behavioral symptoms can be mistaken for withdrawal or the reverse. Never stop a benzodiazepine abruptly on your own.
Questions to bring, and what to settle before you leave
A review's value depends on what the reviewer knows about daily life, and much of that only a caregiver can supply. The National Institute on Aging advises clinicians to ask whether the person uses a pill organizer and whether anyone oversees intake, so volunteer the honest answer even if oversight is patchy.
Swallowing is worth raising unprompted. The NIA's guidance on managing medicines for a person with Alzheimer's notes that clinicians should ask about liquid forms or crushing when swallowing is difficult — but some pills must be swallowed whole to work, so confirm each one individually rather than crushing across the board. Before the appointment ends, settle these:.
- Which drugs could be stopped, and which are non-negotiable
- Whether any twice- or three-times-daily dose has a once-daily equivalent
- Whether two doses can be consolidated into one time of day
- Who is responsible for each follow-up item on the to-do list
- The date of the next check-in, written down
Where the guidance runs out
Deprescribing has far more structure behind it than it did a few years ago. A 2025 clinical practice guideline on polypharmacy in people aged 65 and older issued 185 consensus-based recommendations plus 70 good-practice statements, covering both specific drug classes and general principles for stopping. Note what "consensus-based" means: expert agreement, not a trial that randomized people to stopping versus continuing each drug.
Recommendations of that kind are a strong starting point for a conversation, not a verdict that overrides a prescriber's knowledge of one patient. The practical consequence is that one review is rarely enough. Reviews are annual, tapers need close follow-up, and cognition changes — so a regimen that a caregiver can manage today may need to be simplified again within the year.
Frequently Asked Questions
Does the review cost anything or use a copay?
No. Medicare Part D plans must offer the Comprehensive Medication Review free to eligible enrollees, and it can be done by telehealth rather than in person.
Can a caregiver attend, or go instead?
Yes — and it is usually better. The reviewer needs to know which doses are actually missed and who oversees intake, which the caregiver often knows more accurately than the patient does.
The plan says my parent isn't eligible. What now?
Ask the pharmacy about a medication review outside the Medicare program, and bring the full bag of bottles to the next annual wellness visit or specialist appointment.
Will the pharmacist change the prescriptions?
Generally no. The review produces recommendations and a written to-do list; the prescriber makes the changes, which is why the follow-up items need an owner and a date.